Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: Etravirine

Journal of Pharmaceutical Sciences

Volumn 100, Issue 1, 2011, Pages 260-274

  Weuts, Ilse ^a   Van Dycke, Frederic ^a   Voorspoels, Jody ^a   De Cort, Steve ^a   Stokbroekx, Sigrid ^a   Leemans, Ruud ^a   Brewster, Marcus E ^a   Xu, Dawei ^b   Segmuller, Brigitte ^b   Turner, Ya Tsz A ^c   Roberts, Clive J ^c   Davies, Martyn C ^c   Qi, Sheng ^d   Craig, Duncan Q M ^d   Reading, Mike ^d  

^a JOHNSON AND JOHNSON   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Amorphous; Characterization; Etravirine; HPMC; Solid dispersion

Indexed keywords

ETRAVIRINE; HYDROXYPROPYLMETHYLCELLULOSE;

ARTICLE; DISPERSION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG STABILITY; FILM COATING; PHYSICAL CHEMISTRY; POWDER; SPRAY DRYING;

EID: 78650039081     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22242     Document Type: Article

References (57)

1. Lipinski CA. 2000. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44: 235-249.
2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computatorial approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26.
3. Lipinski CA. 2001. Avoiding investment in doomed drugs. Curr Drug Discov 1: 17-19.
4. Lipinski C, Hopkins A. 2004. Navigating chemical space for biology and medicine. Nature 432: 855-862.
5. Lipinski CA. 2006. The anti-intellectual effect of intellectual property. Curr Opin Chem Biol 10: 380-383.
6. Liu R. 2000. Water insoluble drug formulation. Interpharm Press. Denver, CO.
7. Dressman J, Butler J, Hempenstall J, Reppas C. 2001. The BCS: Where do we go from here? Pharm Tech 25: 68-76.
8. Brewster M, Loftsson T. 2007. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev 59: 645-6766.
9. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersion. Eur J Pharm Biopharm 50: 47-60.
10. Serajuddin AT. 1999. Solid dispersion of poorly water-soluble drugs. Early promises, subsequent problems and recent breakthroughs. J Pharm Sci 88: 1058-1066.
11. Hancock BC. 2002. Disordered drug delivery: Destiny, dynamics and the Deborah number. J Pharm Pharmacol 54: 737-746.
12. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Janssen P, De Corte B, Vingerhoets J, Pauwels R, de Béthune MP. 2004. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse tgranscriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 48: 4680-4686.
13. Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L, Jochmans D, Andries K, Pauwels R, de Béthune MP. 2005. TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J Virol 79: 12773-12782.
14. Habib MJ. 2000. Fundamentals of solid dispersions. In: Habib MJ, editor. Pharmaceutical solid dispersion technology. Boca Raton, FL: CRC Press. pp 7-36.
15. Craig DQM. 2002. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm 231: 131-144.
16. Qi S, Weuts I, De Cort S, Stokbroekx S, Leemans R, Reading M, Belton P, Craig DQM. 2009. An investigation into the crystallization behavior of an amorphous cryomilled pharmaceutical material above and below the glass transition. J Pharm Sci 99: 196-208.
17. Shah B, Kakumanu VK, Bansal AK. 2006. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J Pharm Sci 95: 1641-1665.
18. Six K, Murphy J, Weuts I, Craig DQM, Verreck G, Peeters J, Brewster M, Van den Mooter G. 2003. Identification of phase separation in solid dispersions of Itraconazole and Eudragit® E100 using microthermal analysis. Pharm Res 20: 135-138.
19. Bauer-Brandl A. 1996. Polymorphic transition of cimetidine during manufacture of solid dosage forms. Int J Pharm 140: 195-206.
20. Shi HG, Farber L, Michaels JN, Dickey A, Thompson KC, Shekular SD, Hurter PN, Reynolds SD, Kaufman MJ. 2003. Characterization of crystalline drug nanoparticles using atomic force microscopy and complementary techniques. Pharm Res 20: 479-484.
21. Zhang J, Ebbens S, Chen X, Jin Z, Luk S, Madden C, Patel N, Roberts CJ. 2006. Determination of the surface free energy of crystalline and amorphous lactose by atomic force microscopy adhesion measurements. Pharm Res 23: 401-407.
22. Ward S, Perkins M, Zhang J, Roberts CJ, Madden CE, Luk SY, Patel N, Ebbens SJ. 2005. Identifying and mapping surface amorphous domains. Pharm Res 22: 1195-1202.
23. Price R, Young PM. 2004. Visualization of the crystallisation of lactose from the amorphous state. J Pharm Sci 93: 155-164.
24. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86: 1-12.
25. Yu L. 2001. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Deliv Rev 48: 27-42.
26. Ping G. 2008. Amorphous pharmaceutical solids: Characterization, stabilization and development of marketable formulations of poorly water soluble drugs with improved oral absorption. Mol Pharm 5: 903-904.
27. Mathot VBF. 2001. New routes for thermal analysis and calorimetry as applied to polymeric systems. J Therm Anal Cal 64: 15-35.
28. Chawla G, Bansal AK. 2007. A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug. Eur J Pharm Sci 32: 45-57.
29. Crowley KJ, Zografi G. 2001. The use of thermal methods for predicting glass-former fragility. Thermochim Acta 380: 79-93.
30. Wang L, Angell CA, Richert R. 2006. Fragility and thermodynamics in nonpolymeric glass-forming liquids. J Chem Phys 125: 074505.
31. Verreck G, Six K, Van den Mooter G, Baert L, Peeters J, Brewster ME. 2003. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion-Part 1. Int J Pharm 251: 165-174.
32. Bhugra C, Pikal MJ. 2008. Role of thermodynamic, molecular and kinetic factors in crystallization from the amorphous state. J Pharm Sci 97: 1329-1349.
33. Gordon M, Taylor JS. 1952. Ideal copolymers and the second-order transitions of synthetic rubbers. I. Non-crystalline copolymers. J Appl Chem 2: 493-501.
34. Simha R, Boyer RF. 1962. On a general relation involving the glass temperature and coefficients of expansion of polymers. J Chem Phys 37: 1003-1007.
35. Van den Mooter G, Van den Brande J, Augustijns P, Kinget R. 1999. Glass forming properties of benzodiazepines and co-evaporate systems with poly(hydroxyethyl methacrylate). J Therm Anal Calor 57: 493-507.
36. Lubach J, Xu D, Segmuller B, Munson EJ. 2007. Investigation of the effects of pharmaceutical processing upon solid-state NMR relaxation times and implications to solid-state stability. J Pharm Sci 96: 777-787.
37. Geppi M, Mollica G, Borsacchi S, Veracini CA. 2008. Solid-state NMR studies for pharmaceutical systems. Appl Spectrosc Rev 43: 202-302.
38. Hancock BC, Shamlin SL, Zografi G. 1995. Molecular mobility of glassy pharmaceutical solids. Pharm Res 12: 799-806.
39. Franks F. 2003. Scientific and technological aspects of aqueous glasses. Biophys Chem 105: 251-261.
40. Six K, Verreck G, Peeters J, Binnemans K, Berghmans H, Augustijns P, Kinget R, Van den Mooter G. 2001. Investigation of thermal properties of glassy itraconazole: Identification of a monotropic mesophase. Thermochim Acta 376: 175-181.
41. Six K, Verreck G, Peeters J, Augustijns P, Kinget R, Van den Mooter G. 2001. Characterization of glassy itraconazole: A comparative study of its molecular mobility below Tg with that of structural analogs with MTDSC. Int J Pharm 213: 163-173.
42. Weuts I, Kempen D, Six K, Peeters J, Verreck G, Brewster M, Van den Mooter G. 2003. Evaluation of different calorimetric methods to determine the glass transition temperature and molecular mobility below Tg for amorphous drugs. Int J Pharm 259: 17-25.
43. Bunjes H, Rades T. 2005. Thermotropic liquid crystalline drugs. J Pharm Pharmacol 57: 807-816.
44. Stevenson CL, Bennett DB, Lechuga-Ballesteros D. 2005. Pharmaceutical liquid crystals: The relevance of partially ordered systems. J Pharm Sci 94: 1861-1880.
45. Gilis PA, De Conde V, Vandecruys R. 1997. Beads having a core coated with an antifungal and a polymer. US patent 5633015.
46. Brewster ME, Vandecruys R, Verreck G, Noppe M, Peeters J. 2002. A novel cyclodextrin-containing glass thermoplastic systems (GTS) for formulating poorly water soluble drug candidates: Preclinical and clinical results. J Incl Phenom Macro Chem 44: 35-38.
47. Six K, Berghmans H, Leuner C, Dressman J, Van Werde K, Mullens J, Benoist L, Thimon M, Meublat L, Verreck G, Peeters J, Brewster M, Van den Mooter G. 2003. Characterization of solid dispersions of itraconazole and hydroxypropylmethyl-cellulose prepared by melt extrusion-Part II. Pharm Res 20: 1047-1054.
48. Peeters J, Neeskens P, Tollenaere JP, Van Remoortere P, Brewster ME. 2002. Characterization of the interaction of 2-hydroxypropyl-β-cyclodextrin with itraconazole at pH 2, 4 and 7. J Pharm Sci 91: 1414-1422.
49. Cha B, Oh J. 1998. An itraconazole exhibition an improved solubility, a method of preparing the same a pharmaceutical composition for oral administration comprising the same. WO9857967.
50. Peeters J, Verreck G, Vandecruys R, Brewster M. 2008. Dissolution and human bioavailability in supersaturating drug delivery systems: Formulations of itraconazole. 2008 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, Abstract No. T2097.
51. Tajber L, Corrigan OI, Healy AM. 2005. Physicochemical evaluation of PVP-thiazide diuretic interactions in co-spray dried composites-Analysis of glass transition composition relationships. Eur J Pharm Sci 24: 553-563.
52. Gupta P, Bansal AK. 2005. Molecular interactions in celecoxib-PVP-meglumine amorphous systems. J Pharm Pharmacol 57: 303-310.
53. Craig DQM, Royall PG, Kett VL, Hopton ML. 1999. The relevance of the amorphous state to pharmaceutical dosage forms: Glassy drugs and freeze dried systems. Int J Pharm 179: 179-207.
54. Kawakami K, Pikal MJ. 2005. Calorimetric investigation of the structural relaxation of amorphous materials: Evaluating validity of the methodologies. J Pharm Sci 94: 948-965.
55. Shamblin SL, Hancock BC, Dupuis Y, Pikal MJ. 2000. Interpretation of relaxation time constants for amorphous pharmaceutical systems. J Pharm Sci 89: 417-427.
56. Weuts I, Kempen D, Decorte A, Verreck G, Peeters J, Brewster M, Van den Mooter G. 2004. Phase behavior analysis of solid dispersions of loperamide and two structurally related compounds with the polymers PVP-K30 and PVP-VA64. Eur J Pharm Sci 22: 375-385.
57. Weuts I, Kempen D, Decorte A, Verreck G, Peeters J, Brewster M, Van den Mooter G. 2005. Physical stability of the amorphous state of loperamide and two fragment molecules in solid dispersions with the polymers PVP-K30 and PVA-VA64. Eur J Pharm Sci 25: 313-320.